Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19914470 | 0.81 | CYP2A6 (0.36) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL2011544 | 0.76 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL18725846 | 0.76 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL164774 | 0.73 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL17010916 | 0.73 | CYP2A6 (0.52) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL155613 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL760406 | 0.71 | CYP2A6 (0.55) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL534539 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL226062 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL153350 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-3125322-A1 | ORGANIC TRANSISTOR, COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICE, MATERIAL FOR ORGANIC TRANSISTOR, COATING LIQUID FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICE, METHOD FOR MANUFACTURING ORGANIC TRANSISTOR, METHOD FOR MANUFACTURING ORGANIC SEMICONDUCTOR FILM, ORGANIC SEMICONDUCTOR FILM FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICE, AND METHOD FOR SYNTHESIZING ORGANIC SEMICONDUCTOR MATERIAL | Fujifilm Corporation (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-9112157-B2 | Hole transport materials including OLED applications | SOLVAY USA, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9112157-B2 | Hole transport materials including OLED applications | SOLVAY USA, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | CYP2A6 3831/4885DYRK1A 3925/4885PTPRC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.